IP Verse

Medicaments For Increasing Endogenous Erythropoietin (Epo)

Patent No. EP2298301 (titled "Medicaments For Increasing Endogenous Erythropoietin (Epo)") was filed by Fibrogen on Dec 6, 2002. The application was issued on Nov 16, 2022.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
AKEBIA THERAPEUTICSApr 3, 2019JONES DAY

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2298301

FIBROGEN
Application Number
EP10181796A
Filing Date
Dec 6, 2002
Status
Patent Maintained As Amended
Oct 14, 2022
Publication Date
Nov 16, 2022
External Links
Slate, Register , Google Patents